King's College London, School of Cancer and Pharmaceutical Studies, Translational Oncology & Urology Research (TOUR), TOUR, Guy's Hospital, 3rd Floor Bermondsey Wing, London, SE1 9RT, UK.
The Royal Marsden, Department Urology, London, UK.
BMC Urol. 2020 Jun 3;20(1):64. doi: 10.1186/s12894-020-00634-1.
Bladder cancer (BC) treatment can have a detrimental effect on the sexual organs of patients and yet assessment of sexual health needs has been greatly overlooked for these patients compared to those who have undergone other cancer therapies.
This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines in July 2019. Studies were identified by conducting searches for Medline (using the PubMed interface), the Cochrane Central Register of Controlled Trials (CENTRAL) and Ovid Gateway (Embase and Ovid) using a list of defined search terms.
15 out of 37 studies included men only, 10 studies women only and 11 both sexes. Most participants were aged 50 to 65 years. Most studies (n = 34) focused on muscle invasive BC and only three on non-muscle invasive BC. Measurements of sexual dysfunction, including erection, ejaculation, firmness and desire, were the most commonly used measurements to report sexual health in men. In women, lubrification/dryness, desire, orgasm and dyspareunia were the most commonly reported. Twenty-one studies evaluated sexual dysfunction based on validated questionnaires, two with a non-validated questionnaire and through interviewing participants.
While recognition of the importance of the inclusion of psychometric measurements to assess sexual health is growing, there is a lack of consistent measures to assess sexual health in BC. With the focus on QoL arising in cancer survivorship, further studies are needed to develop, standardize and implement use of sexual health questionnaires with appropriate psychometrics and social measures to evaluate QoL in BC patients.
"PROSPERO does not currently accept registrations for scoping reviews, literature reviews or mapping reviews. PROSPERO is therefore unable to accept your application or provide a registration number. This decision should not stop you from submitting your project for publication to a journal."
膀胱癌(BC)的治疗可能会对患者的生殖器官产生不利影响,但与接受过其他癌症治疗的患者相比,对这些患者的性健康需求评估却被大大忽视。
本综述于 2019 年 7 月按照系统评价和荟萃分析的首选报告项目(PRISMA)指南进行。通过使用定义的搜索词列表,在 Medline(使用 PubMed 界面)、Cochrane 中央对照试验注册中心(CENTRAL)和 Ovid 网关(Embase 和 Ovid)上进行搜索,确定了研究。
37 项研究中有 15 项仅纳入男性,10 项仅纳入女性,11 项纳入了男女两性。大多数参与者的年龄在 50 至 65 岁之间。大多数研究(n=34)侧重于肌肉浸润性 BC,仅有 3 项研究关注非肌肉浸润性 BC。勃起、射精、硬度和欲望等性功能障碍的测量是报告男性性健康最常用的测量方法。在女性中,润滑/干燥、欲望、性高潮和性交痛是最常报告的。21 项研究基于验证性问卷评估性功能障碍,2 项研究使用非验证性问卷,还有 21 项通过采访参与者进行评估。
虽然人们越来越认识到纳入心理测量学测量来评估性健康的重要性,但在 BC 中缺乏评估性健康的一致测量方法。随着癌症生存者生活质量的重视,需要进一步研究开发、标准化和实施具有适当心理测量学和社会测量的性健康问卷,以评估 BC 患者的生活质量。
“PROSPERO 目前不接受范围综述、文献综述或映射综述的注册。因此,PROSPERO 无法接受您的申请或提供注册号码。这一决定不应阻止您向期刊提交您的项目以供发表。”